Susquehanna International Group, LLP Next Cure, Inc. Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.29 - $1.84 $33,781 - $48,184	-26,187 Reduced 66.67%	13,094 $16,000
Q2 2023 Aug 11, 2023	BUY	$1.47 - $1.86 $16,269 - $20,586	11,068 Added 39.23%	39,281 $70,000
Q1 2023 May 16, 2023	SELL	$1.46 - $1.83 $28,826 - $36,131	-19,744 Reduced 41.17%	28,213 $41,000
Q4 2022 Feb 14, 2023	BUY	$1.2 - $3.07 $57,548 - $147,227	47,957 New	47,957 $67,000
Q1 2022 May 16, 2022	BUY	$4.76 - $6.24 $98,517 - $129,149	20,697 Added 22.92%	111,012 $540,000
Q4 2021 Feb 14, 2022	BUY	$5.7 - $9.1 $173,325 - $276,712	30,408 Added 50.76%	90,315 $542,000
Q3 2021 Nov 15, 2021	BUY	$6.74 - $8.02 $247,641 - $294,670	36,742 Added 158.61%	59,907 $404,000
Q2 2020 Aug 14, 2020	BUY	$21.19 - $40.2 $297,655 - $564,689	14,047 Added 154.06%	23,165 $497,000
Q1 2020 May 15, 2020	BUY	$32.32 - $58.37 $43,793 - $79,091	1,355 Added 17.45%	9,118 $338,000
Q4 2019 Feb 14, 2020	BUY	$25.0 - $92.22 $194,075 - $715,903	7,763 New	7,763 $437,000

15.9M

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $36.4M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.